Metabolix labeled a risky, speculative stock

Bioplastics producer Metabolix has survived the termination of its joint venture with DSM but is struggling to develop new sources of revenue. A shrinking cash reserve and the need to acquire financing for a new commercial-scale facility before substantial revenue growth can be achieved make a further decline in the company’s share price likely.

Only speculative investors with a high tolerance for risk should consider buying this company’s shares.

… Full text: seekingalpha.com/article/1705122-bioplastics-producer-metabolix-is-in-a-race-against-the-clock

Tags: price, investing, risk-tolerant investors